ATIC

Across TCGA pan-cancer cohorts, ATIC mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ATIC’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ATIC mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ATIC is over-expressed in tumor.

CCRCC, LUAD, and LSCC are the cancer types where ATIC tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATIC mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	+0.402	<.001	12	view →
LUAD	Female	All	+0.445	<.001	9	view →
LSCC	Male	III,IV	+0.347	<.001	8	view →
COAD	Female	All	+0.153	<.001	6	view →
PDAC	Male	All	+0.345	<.001	5	view →
HNSC	Male	II,III,IV	+0.085	.028	3	view →
OV	All	All	+0.380	.012	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ATIC–CCRCC

Open the CCRCC breakdown →